UNH vs WAY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
UNH is the larger of the two ($308.55B market cap): the incumbent the market prices for continued execution (14.67x forward earnings, beta 0.52). WAY is the smaller challenger ($5.13B), priced similarly on forward earnings (14.13x): more room to run, but more to prove. WAY is expected to grow revenue faster (10% vs 3% next year) at a similar price (14.13x vs 14.67x forward earnings). The case for UNH rests on its own driver (Optum growth engine): if you believe in that, UNH fits; if you believe in what the numbers show today, WAY does.
UNH vs WAY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | UNH | WAY | What it tells you |
|---|---|---|---|
| Market cap | $308.55B | $5.13B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.67 | 14.13 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 19.65 | 38.66 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.52 | 0.11 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 43% of range | 46% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.15 | 1.27 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how UNH and WAY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. UNH and WAY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined UNH and WAY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does UnitedHealth Group (UNH) do?
UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.
What does Waystar Holding (WAY) do?
Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix.
UNH vs WAY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- UNH drivers: Optum growth engine; Medicare Advantage scale.
- WAY drivers: AI-driven revenue cycle automation; Land-and-expand with high retention.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. For WAY, concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share.
UNH or WAY: which should you pick?
If the story you believe is UNH's (Optum growth engine), UNH is the more direct way to own it; if it is WAY's (AI-driven revenue cycle automation), WAY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the UNH and WAY guides.
UNH vs WAY: the full fundamentals
UNH. The trailing P/E of about 19.7x is still inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 14.7x, down from about 17x in October as the share price fell about 18% in a month. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. Twenty-five analysts have a mean target near $476, well above the November 20 close, while HSBC sits at $385 and TD Cowen at $455.
WAY. Waystar closed at about $26.72 on November 20, 2026, up about 10% over three months and well above its 52-week low near $17.26, but down roughly 23% from a year earlier. Q3 2026 revenue rose ~21% to ~$326 million and adjusted EPS of $0.44 beat the $0.41 estimate, but the trimmed full-year revenue range sent the stock lower. The trailing GAAP P/E near 39 and a market cap of about 4.1 times trailing revenue reflect expectations for continued double-digit growth, while the forward multiple of about 14 times 2027 adjusted EPS looks lower because adjusted figures exclude amortization and stock compensation; the 22 analysts covering the stock carry a mean target near $34.82, and the price also includes some takeover speculation.
Headline figures (approximate, November 2026): UNH shows revenue (ttm) ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year, operating margin ~5.8% (net margin ~3.5%), net income (ttm) ~$15.9 billion (sensitive to medical costs), eps ~$17.52 trailing; Q3 2026 $4.69 vs $4.14 consensus; Q4 consensus ~$2.28; WAY shows revenue (ttm) ~$1.26B (+21% YoY in Q3 2026), q3 2026 adj. eps $0.44 vs $0.41 est., net income (ttm) ~$135M (~11% net margin), q3 2026 adj. ebitda ~$139M (~43% margin).
The bottom line: UNH vs WAY
UNH and WAY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined UNH and WAY exposure against your real portfolio. It is not an investment adviser.
Wondering how UNH or WAY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about UnitedHealth Group
Ask Walnut's AI anything about UNH and see how it fits what you own.
FAQ
What is the difference between UNH and WAY?
+
UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is UNH or WAY the better stock?
+
Neither is universally better. UNH is the larger incumbent; WAY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, UNH or WAY?
+
On forward P/E (as of November 2026), UNH trades at 14.67x and WAY at 14.13x, so WAY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both UNH and WAY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of UNH vs WAY?
+
UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. A proposed federal anti-fraud rule targeting Medicare Advantage is the newest policy risk; it knocked managed-care stocks lower in November 2026, and analysts at TD Cowen called it a potential headwind likely to face legal challenges. The 2026 recovery also raises the bar: even after the November drop, at roughly 14.7x forward earnings the stock prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor. WAY: Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a trailing P/E near 39 leaves little room for a growth or margin stumble, and the November 2026 reaction to a full-year revenue range about 1% below consensus showed how little slack the market gives. The stock remains well below its 52-week high of about $37.51. Part of its rebound from the spring low followed reports of a possible sale, so a process that ends without a deal could take some of it back. Growth is partly acquisition-fueled and net revenue retention eased to about 108%, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history (about $1.48 billion against roughly $279 million of cash as of September 2026). Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell UNH or WAY; figures are approximate and dated (as of November 2026). Verify current data before investing.